By Mary Kangley 
Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
October’s Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter, in relation to COVID-19
| November Rank | October Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 4 | Pfizer | 29,746 | 5,194 | 498 |
| 2 | 5 | AstraZeneca | 4,958 | 1,210 | 75 |
| 3 | 2 | JohnsonandJohnson | 1,473 | 705 | 127 |
| 4 | 6 | GSK | 910 | 282 | 57 |
| 5 | 3 | Gilead | 786 | 206 | 6 |
| 6 | 9 | Sanofi | 722 | 325 | 89 |
| 7 | 1 | Regeneron | 676 | 102 | 14 |
| 8 | 7 | Lilly | 589 | 187 | 11 |
| 9 | 12 | MerckandCo | 524 | 393 | 158 |
| 10 | 11 | Novartis | 463 | 368 | 61 |
| 11 | 8 | Roche | 438 | 210 | 67 |
| 12 | 10 | Abbott | 419 | 360 | 9 |
| 13 | 14 | AbbVie | 395 | 366 | 15 |
| 14 | 24 | Biogen | 347 | 49 | 1 |
| 15 | 13 | Bayer | 336 | 183 | 16 |
| 16 | 19 | NovoNordisk | 230 | 187 | 46 |
| 17 | 15 | Amgen | 172 | 133 | 16 |
| 18 | 16 | Boehringer | 158 | 139 | 45 |
| 19 | 21 | Servier | 120 | 106 | 1 |
| 20 | 22 | Takeda | 104 | 97 | 33 |
| 21 | 17 | BMS | 100 | 74 | 24 |
| 22 | 33 | Ipsen | 75 | 59 | 13 |
| 23 | 18 | Fresenius | 69 | 54 | 25 |
| 24 | 20 | UCB | 67 | 61 | 47 |
| 25 | 23 | Teva | 55 | 50 | 30 |
| 26 | 26 | MerckKGaA | 52 | 45 | 11 |
| 27 | 25 | Allergan | 44 | 3 | 0 |
| 28 | 35 | CSL | 39 | 37 | 3 |
| 29 | 31 | Mylan | 36 | 15 | 3 |
| 30 | 29 | Menarini | 33 | 30 | 17 |
| 31 | 28 | Otsuka | 30 | 6 | 3 |
| 32 | 32 | Chugai | 30 | 0 | 0 |
| 33 | 30 | DaiichiSankyo | 26 | 14 | 4 |
| 34 | 39 | Astellas | 26 | 19 | 0 |
| 35 | 38 | Alexion | 25 | 12 | 2 |
| 36 | 36 | Bausch | 21 | 4 | 1 |
| 37 | 37 | Eisai | 18 | 8 | 1 |
| 38 | 34 | Grifols | 16 | 2 | 0 |
| 39 | 27 | Vertex | 12 | 11 | 0 |
| 40 | 40 | Sun | 10 | 4 | 2 |
| 50 | 50 | MitsubishiTanabePharma | 0 | 0 | 0 |
| 50 | 50 | JiangsuHengrui | 0 | 0 | 0 |
| 50 | 50 | Ono | 0 | 0 | 0 |
| 50 | 50 | Endo | 0 | 0 | 0 |
| 50 | 50 | Meiji | 0 | 0 | 0 |
| 50 | 50 | Yunnan Baiyao | 0 | 0 | 0 |
| 50 | 50 | Aurobindo | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | SumitomoDainippon | 0 | 0 | 0 |
October’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies, in relation to COVID-19
The five pharmaceutical companies that were mentioned the most by healthcare professionals (HCPs) on Twitter during October 2020 were Regeneron, Johnson and Johnson (J&J), Gilead, Pfizer, and AstraZeneca.
For the first time since CREATION.co began tracking in August 2019, Regeneron not only entered the top 5 list, but was the most mentioned pharmaceutical company by HCPs overall. This was due to the endorsement of their experimental monoclonal antibody cocktail for the treatment of COVID-19 by Donald Trump. This came after the outgoing US President tested positive for the virus and was treated with the drugs under a compassionate use request. HCPs responded to Trump’s comments by reminding their networks that the treatment is not yet approved or available for public use.
"As far as we know, the President is the only person in the world to have received this combination of treatments."
NYT also estimates it costs ~ $1.5 million for the Regeneron antibody cocktail.
➡️ Special treatment for he, but not for thee. #COVID19https://t.co/R5yXrBwYm8
— Eric Feigl-Ding (@DrEricDing) October 8, 2020
Notably, before heading to the hospital the president was treated with the highest dose of Regeneron’s monoclonal antibody cocktail. This experimental therapeutic hasn't been authorized or approved by the FDA. Regeneron said he received it under a compassionate use request.(4/12) pic.twitter.com/h9V7iY0olP
— Dr. Sanjay Gupta (@drsanjaygupta) October 3, 2020
As well as this story, HCPs shared links to reports of more of the latest news in COVID-19 treatment.
- The most shared link from HCPs was the STAT News story that the J&J Covid-19 vaccine study had to be paused due to an unexplained illness in participant.
- HCPs also shared Science Mag’s report of the ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug.
- They also posted from CNN Business who stated that Trump has ties to Regeneron and now its stock is surging.
HCPs disseminated information about J&J’s Phase III COVID-19 vaccine candidate trial being paused. This comes after AstraZeneca’s trial with the University of Oxford was also put on hold last month over safety concerns.
Another Covid-19 vaccine study “paused” due to “an unexplained illness in a study participant.” The manufacturer, Johnson & Johnson declined to provide further details. https://t.co/1IAB0GqHg2
— Maryanne Demasi, PhD (@MaryanneDemasi) October 13, 2020
COVID-19 discussion increased by 217% from last month, making up over 56% of the overall conversation about top 50 pharmaceutical companies. Despite no significant spikes in the conversation outside of those relating to COVID-19, HCPs continued to share good news from pharmaceutical companies including successful trials and product approvals.
The field is moving fast towards chemo-free regimens. @NEJM @bmsnews @AmgenOncology @DrHKantarjian pic.twitter.com/8RqYTa6kag
— Mohamad Mohty (@Mohty_EBMT) October 22, 2020
⚠️⚠️ More good news⤵️
Forxiga (#dapagliflozin) is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction
Via @EMA_News @AstraZeneca @secardiologia @IcyfaSemi
📂 https://t.co/3AMkZ3U3Gl pic.twitter.com/K0fAq8U7Nq
— Alfonso Valle (@ValleAlfonso) October 16, 2020
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- In October 2020, CREATION Pinpoint® identified 25,286 healthcare professional (HCP) authored tweets from 10,478 individual HCPs mentioning a top-50 pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 pharmaceutical company between October 1st and October 31st 2020.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (eg. @abbottnews and @abbottglobal) – this only counts as one Company Mention but two Account Mentions.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In October, 649 of these posts mentioned Janssen
